^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + Itari (linperlisib) (PI3Kδ inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer
Published date:
07/20/2023
Excerpt:
Patient-derived HR + ABC xenografts were implanted into immune-humanized NSG mice and subsequently treated with YY20394 (PI3Kδ inhibitor) and camrelizumab….The humanized PDX model showed a favorable initial treatment response to camrelizumab combined with YY20394 and manageable toxicity. YY20394 plus camrelizumab showed a strong inhibitory effect on HR + BC in vivo...Our study suggests PI3Kδ inhibitor could the enhance the efficacy of ICIs in HR + BC PDX models by combating immune suppression and provides a feasible approach that may overcome the resistance of ICIs in HR + BC patients.
DOI:
10.1016/j.heliyon.2023.e18498
